Navigation Links
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Date:5/16/2008

copeia.com" target="_new">http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.

(1) Prescribing Information for Coreg CR(R), Lotensin(R), Avapro(R),

Benicar(R) and Norvasc(R)

(2) American Heart Association news release.

http://americanheart.mediaroom.com/index.php?s=43&item=59. Accessed

April 7, 2008.

(3) AHA 2007 Heart Disease and Stroke Statistics, p. 3.

(4) Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the

Joint National Committee on Prevention, Detection, valuation, and

Treatment of High Blood Pressure. Journal of the American Medical

Association. 2003;289:p.2560-2572.

(5) American Diabetes Association: http://www.diabetes.org/utils/printthispage.jsp?PageID=STATISTICS_233192.

Accessed April 4, 2008.

(6) Diabetes Care, Volume 27, Supplement 1, January 2004.

(7) National Institute of Diabetes and Digestive and Kidney Diseases.

http://kidney.niddk.nih.gov/kudisease
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
...  BioMed Realty Trust, Inc. (NYSE: BMR ) ... with Depomed, Inc. (NASDAQ: DEPO ) at ... a specialty pharmaceutical company, leased approximately 60,000 square feet ... Realty,s multi-tenant Pacific Research Center campus. Commenting ...
... Fla., April 9, 2012 Med-Tek a developer of Healthcare ... physicians, employers and their constituents today announces the launch ... According to the United States Bone ... individuals suffering from musculoskeletal disease ...
Cached Medicine Technology:New 60,000 Square Foot Lease at the Pacific Research Center Signed by Biomed Realty and Depomed 2New 60,000 Square Foot Lease at the Pacific Research Center Signed by Biomed Realty and Depomed 3Med-Tek Launches the First Evidenced Based Opioid Management Program (OMP) 2
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... 2014) The cause of neuronal death in Parkinson,s ... that neurons may be mistaken for foreign invaders and ... the way autoimmune diseases like type I diabetes, celiac ... study was published April 16, 2014, in Nature ... controversial, idea in Parkinson,s disease; but if true, it ...
(Date:4/17/2014)... School of Medicine (BUSM) have discovered that the ... experimental model. The findings, reported in the ... may lead to more effective treatments for alcoholism. ... the leading causes of illness and death in ... by limiting the productivity of workers and necessitating ...
(Date:4/17/2014)... has the potential to ward off depression among retirees, ... published online in The Journals of Gerontology, ... In the article " Internet Use and Depression Among ... Analysis ," the authors report that Internet use reduced ... among their study sample. , Late-life depression affects ...
(Date:4/17/2014)... not uncommon these days to find a colored ribbon representing ... breast cancer. But what color ribbon does one think of ... designated color, for many suffering from the disease, black may ... University study consisting of lung cancer patients, primarily smokers between ... more light on the stigma often felt by these patients, ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... WASHINGTON, Aug. 31 As Congress prepares to return to ... least 102 rallies and other events in 20 states in ... insurance option. , , Events began Aug. ... returns to Washington, D.C.. They are taking place in California, ...
... , , , ... Diego-based MultiGEN Diagnostics Inc. has launched a novel multi-target DNA sequencing ... in molecular diagnostics. , , "Until now, lack ... market, forcing laboratories to adopt number of alternative methods such as ...
... , , VENTURA, Calif., Aug. 31 ... than to receive." However, when the gift one is giving is ... with more than 97 percent organic aloe vera, receiving and giving ... Founded by Rinaldo and Lalla Brutoco, owners of the manufacturer ...
... , , TORRANCE, ... not be top-of-mind for empty-nesters. But keeping with the spirit of ... on nutrition lessons, take stock of your medicine cabinet and challenge ... can still take advantage of summer,s fresh produce, ensuring a consistent ...
... need for meds, helped some lose weight compared to low-fat ... Mediterranean diet, long touted as a healthy eating plan, may ... medications, as well as help them lose weight and lower ... Italian researchers who found that while 70 percent of people ...
... rare autoimmune condition, new report finds , MONDAY, Aug. 31 ... Kennedy still exerts a pull on medical sleuths nearly 50 ... by a U.S. Navy physician claims that Kennedy suffered from ... was diagnosed with as a young man. , In the ...
Cached Medicine News:Health News:'Let's Get it Done!' From Coast to Coast, USAction Affiliates Rally This Week for Quality, Affordable Health Care 2Health News:Cost Effective Solution for Patient Testing: Introducing Comprehensive and Affordable Molecular Diagnosis With Verifiable Accuracy 2Health News:It's Better to Give Than to Receive 2Health News:It's Better to Give Than to Receive 3Health News:Change in Seasons: Ideal Time to Review Healthy Aging Habits 2Health News:Mediterranean Diet May Be Best for Type 2 Diabetes 2Health News:Mediterranean Diet May Be Best for Type 2 Diabetes 3Health News:JFK's Health Problems More Complex Than Thought 2Health News:JFK's Health Problems More Complex Than Thought 3
... systems are fully automated to ... turnaround of highly accurate specific ... monitoring (TDM) results. Using unique ... easy-to-use Array® 360 performs a ...
... Hycor Biomedical Ltd Autostat™II Rheumatoid Factor IgM ... Rheumatoid Factor IgM (RF IgM). Enzyme-linked immunosorbent ... specific IgM Rheumatoid Factor in human serum. ... can be used as an aid in ...
... Traditionally, when choosing a non-contact diagnostic lens, doctors ... field of view and high magnification. Now, ... by Volk Optical, doctors can have both in ... field of view available in a non-contact lens ...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
Medicine Products: